Have Questions?
FILL OUT THE FORM BELOW
TO REQUEST YOUR CASE REVIEW
Latest Bard PowerPort Lawsuit Updates
Our attorneys are reviewing claims from patients whose Bard PowerPort implantable port catheter fractured, migrated, or caused infection, blood clots, or other serious injuries.
Claims are consolidated in MDL 3081, In re: Bard Implanted Port Catheter Products Liability Litigation, in the U.S. District Court for the District of Arizona before Judge David G. Campbell.
To qualify, claimants generally need a documented Bard PowerPort implant followed by a fracture, migration, or related injury requiring surgical removal or treatment for infection, deep vein thrombosis, pulmonary embolism, sepsis, or cardiac complication.
Fill out the form to check your eligibility and find out if you qualify to file a claim.
The litigation alleges that Becton, Dickinson and Company (BD), C.R. Bard, and Bard Access Systems designed and sold a class of implantable port catheters made with a Chronoflex polyurethane and barium sulfate blend that becomes brittle and fractures inside the body. When the catheter fractures, pieces can migrate through the bloodstream to the heart, lungs, or other vital organs.
Injuries being investigated by PowerPort attorneys:
- Catheter fracture (complete or partial breakage of the catheter body)
- Catheter migration to the heart, lungs, or pulmonary arteries
- Deep vein thrombosis (DVT) and pulmonary embolism (PE)
- Cardiac arrhythmia, cardiac tamponade, perforation of the heart wall
- Severe bloodstream infection (catheter-related bacteremia)
- Sepsis and septic shock
- Vascular perforation (superior vena cava, subclavian vein, brachiocephalic vein)
- Hemothorax and pneumothorax from device displacement
- Necrosis or tissue damage at the port site
- Death from any of the above
MDL 3081 Update: The Plaintiffs' Steering Committee has filed a master complaint and short-form complaint. Discovery is active, with bellwether selection underway. Each plaintiff retains an individual claim coordinated through the MDL.
FDA MAUDE database reports document hundreds of adverse events involving Bard PowerPort devices, including reports of catheter fracture, migration, and patient injuries requiring open-heart surgery to retrieve fragments.
Table of Contents
[show]- What is a Bard PowerPort and what fails
- Injuries linked to PowerPort fracture and migration
- Recalled and named PowerPort device models
- MDL 3081 status: court, judge, and bellwether posture
- Who qualifies to file a PowerPort lawsuit
- Compensation available in PowerPort claims
- How to file and statute of limitations
The Bard PowerPort Failure Pattern
(Implanted Port Catheter Injury Claims, May 2026)
An implantable port catheter (also called a port-a-cath, mediport, central venous access device or CVAD, or implantable vascular access port) is a small medical device placed under the skin of the upper chest. It connects to a catheter threaded into a large vein, giving clinicians long-term venous access for chemotherapy, dialysis, antibiotic therapy, blood transfusions, and frequent blood draws. The Bard PowerPort line is a power-injectable category, meaning it is rated for high-pressure contrast injection used in CT imaging.
For oncology patients, a port is often the difference between manageable treatment and weeks of failed IV attempts. For dialysis patients and patients on long-term IV antibiotics, it is everyday infrastructure.
The Bard PowerPort family of devices is at the center of the litigation. Plaintiffs allege that the catheter tubing breaks down in the bloodstream because of a defect in the Chronoflex polyurethane material blended with barium sulfate (the radio-opaque additive that lets clinicians see the catheter on imaging). Over time, the barium particles allegedly weaken the catheter wall. The catheter cracks, fractures, or breaks free of the port body.
When the catheter fails inside the body, the consequences range from manageable (surgical removal and replacement) to catastrophic (fragments migrating to the right atrium, the pulmonary artery, or the heart valves; sepsis from a contaminated retained piece; cardiac tamponade requiring emergency intervention).
"The catheter fractured and migrated to my heart. I needed open-chest surgery to retrieve the piece."
What is a Bard PowerPort and How Does It Fail
The Bard PowerPort is a "power-injectable" implantable port, meaning it is rated for the high-pressure contrast injections used in CT scans and similar imaging. The device has two parts: a reservoir (the port body, accessed by needle through the skin) and a catheter (the flexible tube that carries fluid from the port into a large central vein, usually the superior vena cava).
Failure in the catheter portion is the central allegation. Plaintiffs identify three specific failure modes.
The first is fracture. The catheter wall develops cracks or breaks completely. A fractured catheter can shed fragments directly into the bloodstream.
The second is migration. The catheter or a fractured piece moves from its intended position. Migration into the right atrium, the right ventricle, or the pulmonary artery is documented in case reports. Retrieval typically requires interventional cardiology or open-heart surgery.
The third is thrombus and infection. A damaged catheter surface is a perfect surface for clot formation. Central line-associated bloodstream infection (CLABSI) and catheter-related bloodstream infection (CRBSI) are known and feared complications of any central venous access device. Plaintiffs allege the Bard PowerPort design increased the risk by creating surface irregularities and biofilm-friendly geometry along the failed catheter wall.
The litigation alleges the defendants knew about the failure rate through their own complaint reporting and through the FDA's MAUDE database but did not update warnings or redesign the device fast enough.
- FDA MAUDE database documents hundreds of PowerPort adverse-event reports including fractures and migrations
- Internal Bard / BD documents on Chronoflex / barium sulfate material composition are central to discovery
- Plaintiffs are often cancer patients or dialysis patients with pre-existing serious illness; juries respond strongly to medical-device failures in vulnerable populations
- Bellwether selection underway in D. Ariz., signaling judicial readiness to move cases toward trial
Injuries and Outcomes Reported in PowerPort Cases
The MDL has organized injury claims by severity of intervention required and the strength of causation evidence.
Fragment Migration Requiring Surgical Retrieval
Hard Truth: The signature port-a-cath fracture injury claim. A fractured fragment migrates from the implant site through the venous system to the right atrium, right ventricle, pulmonary artery, or lung. The retained fragment can also cause superior vena cava syndrome from venous obstruction. Retrieval requires interventional cardiology (endovascular snare or basket retrieval) or, in some cases, open-chest surgery. Each procedure carries surgical risk and adds to the damages calculus.
Deep Vein Thrombosis and Pulmonary Embolism
Hard Truth: A damaged catheter surface promotes clot formation. Plaintiffs report DVT in the upper extremities (subclavian, internal jugular, brachiocephalic veins) and life-threatening pulmonary emboli when clots break loose and travel to the lungs. Both conditions require anticoagulation, hospitalization, and ongoing follow-up. Long-term sequelae include post-thrombotic syndrome.
Catheter-Related Bloodstream Infection and Sepsis
Hard Truth: A defective catheter wall creates surface roughness and biofilm-friendly geometry. Plaintiffs report severe central-line infections progressing to sepsis and septic shock. In immunocompromised oncology patients, sepsis carries mortality rates in the double digits. Wrongful death claims in MDL 3081 frequently involve sepsis from a fractured or retained device.
Cardiac Perforation and Tamponade
Hard Truth: The rarest and most catastrophic outcomes. A migrated fragment or distal catheter tip can perforate the right atrium wall, causing pericardial effusion and tamponade (blood compressing the heart). Emergency pericardiocentesis and surgical repair are required to survive. Cardiac tamponade cases anchor the high end of the damages range in the MDL.
Named Devices and Defendants
The MDL targets a defined set of devices and a clear chain of corporate ownership:
Named Devices and Corporate Defendants
The PowerPort ClearVUE family is among the most frequently named device lines in the master complaint. ClearVUE models are marketed as low-profile, power-injectable implantable ports for chemotherapy infusion and contrast-enhanced CT imaging. The Chronoflex polyurethane catheter is the alleged failure point.
The PowerPort isp and PowerPort MRI implantable port models are also named in the litigation. The MRI line is marketed for patients who need imaging compatibility. Failure modes alleged are the same: catheter fracture, migration, and the downstream injuries that follow.
Becton, Dickinson and Company (BD) acquired C.R. Bard in 2017, including the Bard Access Systems product line that includes the PowerPort family. All three entities (BD, C.R. Bard, Bard Access Systems) are named defendants. Liability allocation between the entities is a discovery issue.
The JPML transferred the cases to the District of Arizona because Bard Access Systems is headquartered in Salt Lake City but has substantial operations in Phoenix, and because Judge David G. Campbell has substantial MDL experience. Direct filing in D. Ariz. is permitted under the court's direct-filing order.
The Bigger Defense Pattern
BD and Bard face the same defense playbook used across implantable medical-device litigation: federal preemption (FDA 510(k) clearance arguments), learned-intermediary doctrine (warnings to the implanting physician are sufficient), and individual causation challenges (alternative explanations for catheter failure such as pinch-off syndrome or implantation technique).
None of these defenses defeat the litigation. They shape per-case value and timeline. Plaintiffs prevail when they can document the failure mode, the medical consequence, and the failure-to-warn theory tied to the specific device model.
HARD TRUTH: The 510(k) clearance argument is weaker for PowerPort than for full PMA-approved devices like Paragard. The litigation analysis differs by product. A Bard PowerPort attorney with MDL experience evaluates which defenses apply to the specific device model implanted.
MDL 3081 at a Glance
Key procedural facts every claimant should understand:
- Case caption: In re: Bard Implanted Port Catheter Products Liability Litigation, MDL No. 3081
- Court: U.S. District Court for the District of Arizona
- Judge: Hon. David G. Campbell
- Centralized: August 8, 2023, by the JPML
- Pending cases: Continuing to grow as discovery progresses
- Defendants: Becton, Dickinson and Company (BD); C.R. Bard, Inc.; Bard Access Systems, Inc.
- Bellwether posture: Selection in progress; trials being prepared for upcoming terms
The MDL coordinates pretrial work (discovery, expert challenges, motion practice, bellwether trials) for cases that share the same defendants and the same core failure-mode allegations. Each case proceeds as an individual claim. Tiered settlement matrices in comparable medical-device MDLs have produced individual recoveries spanning a wide range based on injury severity.
Who Qualifies to File a Bard PowerPort Lawsuit
Eligibility turns on three things: a documented Bard PowerPort implant, a qualifying injury, and a timely filing.
- Implant documentation: Operative report from port placement showing the device manufacturer (Bard) and model. Insurance claim records, hospital billing, and device serial numbers in the medical record all help.
- Qualifying injury: Catheter fracture or migration confirmed by imaging; surgical or interventional retrieval; deep vein thrombosis, pulmonary embolism, sepsis, septic shock, cardiac perforation, cardiac tamponade, or other documented complication causally linked to the device.
- Treatment records: Imaging (chest X-ray, fluoroscopy, CT angiogram, echocardiogram), interventional cardiology or surgical reports, infectious-disease consultations, oncology or nephrology notes.
- Diagnosis date: Failure or complication within the applicable statute-of-limitations window for your state. The discovery rule typically applies for latent-injury product cases.
- Wrongful death: Cases where a PowerPort failure caused or contributed to death of a cancer or dialysis patient. Surviving family may file. The clock typically runs from the date of death.
If you do not have all the records, share what you have. Hospitals retain operative reports and device-implant logs that an experienced PowerPort lawyer can request through standard medical-record subpoenas.
Compensation Available in Bard PowerPort Claims
Damages in a successful product-liability claim cover both economic and non-economic losses, and where evidence supports it, punitive damages.
Economic damages: hospitalization costs for retrieval and complication treatment, interventional cardiology fees, ICU stays for sepsis or tamponade, ongoing follow-up imaging and anticoagulation, lost wages during recovery, and future medical care if long-term sequelae (post-thrombotic syndrome, cardiac valve injury) developed.
Non-economic damages: pain and suffering from the failure event and the corrective procedures, emotional distress, loss of consortium, and the psychological impact of an unplanned cardiac or septic emergency on top of an existing cancer or dialysis diagnosis.
Punitive damages: available where the evidence supports a finding that BD and Bard knew about the Chronoflex/barium-sulfate failure rate and continued to sell the device without adequate warnings. Internal corporate documents discovered in MDL 3081 will determine whether punitive arguments are supported.
The intake review explains how settlement structures in implantable medical-device cases typically tier values, which sit alongside other active medical-device cases our attorneys handle like the Paragard IUD breakage litigation.
What PowerPort Settlement Values May Look Like
It is too early to project specific PowerPort settlement tiers. Bellwether trials have not yet returned verdicts. Comparable implantable-device matrices have tiered payouts by injury severity, treatment burden, surgical retrieval complexity, and whether the failure caused or contributed to death.
Cardiac perforation, tamponade, septic shock, and wrongful death cases anchor the high end. Cases involving straightforward retrieval without major complication sit lower in the tier. Each plaintiff's case is valued individually.
For broader context on how injury claims are valued, see our explanation of what your injury case is worth and how the multiplier method and per diem method work in serious-injury claims.
Filing Deadlines and Procedural Issues
The SOL clock typically starts when the plaintiff knew or should have known that the catheter failure caused the injury. For most plaintiffs, that date is the day imaging confirmed fracture or migration. For sepsis or DVT cases, the connection to the device may be discovered later, extending the clock under state-specific discovery-rule analysis.
Product-liability statutes of limitations range from 1 year (Louisiana, Tennessee) to 6 years. Some states have statutes of repose that bar claims regardless of when the failure occurred. Your home state determines the deadline and the substantive law applied to your case. A free case review confirms your filing window.
MDL 3081 has a direct-filing order that lets plaintiffs file in the District of Arizona while preserving home-state-law advantages. Direct filing avoids removal complications and locks in MDL status for coordinated discovery and bellwether eligibility.
If a PowerPort failure caused or contributed to death (sepsis, cardiac tamponade, pulmonary embolism), the wrongful death clock typically starts from the date of death rather than the diagnosis date. Surviving spouses, children, and (in some states) parents have standing. See our overview of wrongful death claims.
Defenses and Hurdles in Bard PowerPort Cases
Three contested fronts dominate the litigation.
First, federal preemption. BD and Bard argue that FDA 510(k) clearance of the PowerPort device family preempts state-law design and warning claims. The 510(k) pathway is a weaker preemption argument than full Premarket Approval (PMA), but the defense raises it on motion. Plaintiffs frame allegations around manufacturing-defect and parallel state-law theories that survive preemption.
Second, alternative cause. The defense will argue that any individual catheter failure was caused by physician technique (improper insertion site, pinch-off syndrome between the clavicle and first rib, suturing too tightly), patient anatomy, or general medical-device complications. Operative reports and detailed surgical records help rebut these arguments.
Third, statute of limitations and product identification. The defense will contest whether the device that failed was actually Bard-manufactured and whether the claim was timely. Implant records and device serial numbers anchor product identification. The same defense playbook appears across implantable-device litigation, including the Philips CPAP recall cases in MDL 3014.
None of these defenses defeat the litigation. They affect timeline and per-case value.
How to File a Bard PowerPort Lawsuit
The intake process is straightforward when you work with a firm familiar with MDL 3081.
Step one: free case review. Share your implant date, the device manufacturer and model (if known), the failure event, and the corrective treatment.
Step two: medical record collection. We pull operative reports for the original port placement, imaging documenting fracture or migration, interventional or surgical retrieval records, and treatment records for any infection, DVT, PE, or cardiac complication.
Step three: filing. Most cases are filed directly in MDL 3081 in the D. Ariz. under the court's direct-filing order.
Step four: plaintiff fact sheet. The MDL requires a detailed fact sheet documenting medical history, device timeline, complication course, and damages. We complete this with you.
Step five: discovery and resolution. Through bellwether outcomes, individual settlement, or remand for trial in your home court.
Contingency fee. No money out of pocket. No fee unless we recover for you.
Time Pressure: Why Sooner Is Better Than Later
The discovery rule helps preserve PowerPort claims even when the failure occurred years ago, but statutes of repose in some states can close the door regardless of when the injury was discovered. Hospital implant records get archived. Memory of the specific device model fades.
If your Bard PowerPort fractured, migrated, or caused a serious complication, the case review costs nothing and clarifies your filing window. Waiting can close doors that did not need to close.
Bard PowerPort Lawsuit: Frequently Asked Questions
- Q: How do I know if my port is a Bard PowerPort?
-
A: Check the operative report from the port placement procedure. The report identifies the manufacturer and model number. Hospital implant logs, billing records, and the implant card issued at discharge also identify the device. If you cannot find the records, your attorney can subpoena them. Most PowerPort devices were implanted between roughly 2000 and the present, with the most-claimed models dating from the early 2010s forward.
- Q: My port broke years ago. Can I still file a Bard PowerPort lawsuit?
-
A: Probably yes. The discovery rule preserves many latent-injury product-liability claims. The clock typically starts when a reasonable person would have linked the injury to the device, not when the device was implanted. The MDL 3081 coordinated docket is still accepting new plaintiffs. A free case review confirms your filing window under your state's statute of limitations.
- Q: What is the average PowerPort settlement amount?
-
A: A global settlement matrix has not been finalized. Bellwether trials are being prepared. Comparable implantable medical-device matrices tier values by injury severity, surgical intervention complexity, and survival vs. fatal outcome. Cardiac tamponade, septic shock, and wrongful death cases anchor the high end. Cases involving straightforward retrieval without major complication sit lower. A Bard PowerPort attorney evaluates the specific facts of your case.
- Q: My loved one died of sepsis after a PowerPort infection. Can I sue?
-
A: Yes. Wrongful death and survival action claims are part of MDL 3081. Surviving family members may pursue both wrongful death damages (for the family's losses) and a survival action (for the decedent's pre-death pain and suffering). The wrongful death clock typically runs from the date of death. See our overview of wrongful death claims.
- Q: Was the Bard PowerPort recalled?
-
A: The Bard PowerPort family has not been subject to a Class I recall as of this writing. The litigation rests on the failure-to-warn and design-defect theories rather than a formal recall. The FDA MAUDE database documents adverse-event reports that plaintiffs cite as evidence the defendants knew about the failure pattern.
- Q: How do I find a PowerPort lawyer near me?
-
A: Most cases are filed directly in MDL 3081 in the District of Arizona under the court's direct-filing order, which preserves home-state-law advantages. You do not need an attorney physically located in your home state. You want a PowerPort law firm with MDL experience, the resources to fund medical-record collection and expert review, and a documented relationship with the plaintiffs' steering committee. The case review is free.
- Q: What does a Bard PowerPort attorney cost?
-
A: Contingency fee. You pay no out-of-pocket fees. Attorney fees come from money recovered in your case. If we do not recover, you owe nothing. This is the standard structure across product-liability and MDL practice.
- Q: Is a port-a-cath the same as a Bard PowerPort?
-
A: Port-a-cath, mediport, central venous access device (CVAD), and implantable vascular access port are general terms for the same type of device. Bard PowerPort is a specific manufacturer's brand within that category. The lawsuit targets Bard-manufactured devices specifically. If your port-a-cath was made by another manufacturer (AngioDynamics, Smiths Medical, Medcomp, B. Braun), the MDL 3081 claim does not apply, though other product-liability paths may exist depending on the device and failure mode. Your operative report identifies the manufacturer.
- Q: Is the Bard PowerPort lawsuit a class action?
-
A: No. MDL 3081 is multidistrict litigation, which coordinates many individual lawsuits for pretrial work. Each plaintiff retains a separate claim with a separate settlement value tied to the specific injury and treatment course. Class actions require near-identical claims across all class members and are uncommon in modern personal-injury product-liability work. A Bard PowerPort lawyer files an individual claim on your behalf within the coordinated MDL.
- Q: My chemo extravasated through the port and caused tissue damage. Does that qualify?
-
A: Possibly yes, particularly when the extravasation was caused by a documented PowerPort fracture, leak, or migration rather than infiltration around an intact device. Vesicant chemotherapy agents (anthracyclines such as doxorubicin, vinca alkaloids such as vincristine) cause severe tissue necrosis when they leak into surrounding tissue. If imaging or operative findings tie the extravasation to a device failure, the case may qualify under MDL 3081. Operative reports and oncology notes are the key documentation.
Talk to a Bard PowerPort Lawyer Today
If your Bard PowerPort fractured, migrated, or caused infection, blood clots, cardiac injury, or other serious harm, you may qualify to file a claim in MDL 3081.
The case review is free and confidential. We handle PowerPort cases on contingency. You owe nothing unless we recover compensation for you.
Cases involving fatal outcomes are pursued through wrongful death and survival action claims alongside the MDL.
Free Case Evaluation
FILL OUT THE FORM BELOW
TO REQUEST YOUR CASE REVIEW
External Resources
Legal Representation
"Speak with our medical-device attorneys for a free, confidential review of your potential Bard PowerPort claim. Past results vary based on the unique facts of each case."
Find out more >>